心血管

订阅

MedSci主页 / 所有栏目 / 心血管

QICC 2013 张发宝：CONSORT规范中的临床研究设计要点

2013-08-05 MedSci MedSci原创

QICC2013钱江会MedSciCONSORT规范临床研究设计
关注

第七届钱江国际心血管病会议于2013年8月2日在浙江省人民大会堂拉开帷幕，本界大会由浙江省医学会心血管病分会主办，由韩国血管成形术峰会（TSCI）、香港心脏专家学院（HKCC）、新加坡心脏学会（SCS）等单位支持。 受第七届钱江国际心血管病会议邀请，MedSci张教授于8月3日在临床研究论坛上发表题为《CONSORT规范中的临床研究设计要点》主题演讲，受到广泛关注。

第七届钱江国际心血管病会议于2013年8月2日在浙江省人民大会堂拉开帷幕，本界大会由浙江省医学会心血管病分会主办，由韩国血管成形术峰会（TSCI）、香港心脏专家学院（HKCC）、新加坡心脏学会（SCS）等单位支持。
受第七届钱江国际心血管病会议邀请，MedSci张发宝博士于8月3日在临床研究论坛上发表题为《CONSORT规范中的临床研究设计要点》主题演讲，受到广泛关注。



MedSci张博士讲到，临床研究设计需要遵循相关规范，才能保证其高质量。张博士通过受试者筛选和研究终点设置两方面，从如何设计，常见研究设计形式及其报告规范，纳入标准和排除标准，主要终点，复合终点等，引入大量实例进行讲解，现场气氛热烈。但是，张博士还提到，受试者筛选以及终点设置只是设计中的两个小环节，其他环节也同样是关键，这些都是保证临床研究的关键。
MedSci将一如既往，从临床设计入手，强化客户树立临床研究意识、挖掘临床研究创新点、规范临床研究过程以及资料收集整理、整理高质量临床成果为服务理念，与中国临床科研人员进行全面、深入地合作。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2014-04-02 ms6980045490879608

    #CONSORT规范#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2014-03-28 xqptu

    #QICC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2013-08-07 docwu2019

    #ICC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2013-08-07 tomyang91

    #CONSORT#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2013-08-07 tomyang91

    #CONSORT#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2013-08-07 lishiwen

    #临床研究设计#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2021209, encodeId=d3a22021209d4, content=<a href='/topic/show?id=89df506ea9' target=_blank style='color:#2F92EE;'>#CONSORT规范#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5067, encryptionId=89df506ea9, topicName=CONSORT规范)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLx96cCLjNYsHar1XErTVibOydfEC9iaYgrXp3SicXwntSAEDeQAlM2vLqTfm6oPORxaib3UIgyHQJJ7A/132, createdBy=36f02500138, createdName=ms6980045490879608, createdTime=Wed Apr 02 06:39:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792925, encodeId=bacf1e9292506, content=<a href='/topic/show?id=bb711495efa' target=_blank style='color:#2F92EE;'>#QICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14957, encryptionId=bb711495efa, topicName=QICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Fri Mar 28 18:39:00 CST 2014, time=2014-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461985, encodeId=2c23146198511, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558462, encodeId=4fad1558462a5, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564471, encodeId=176c15644e131, content=<a href='/topic/show?id=a988506424' target=_blank style='color:#2F92EE;'>#CONSORT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5064, encryptionId=a988506424, topicName=CONSORT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c55a14990568, createdName=tomyang91, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585663, encodeId=c2d71585663d2, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed Aug 07 08:39:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5991, encodeId=e59c5991a8, content=现场参与，确实很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=starmed, createdTime=Mon Aug 05 18:33:00 CST 2013, time=2013-08-05, status=1, ipAttribution=)]
    2013-08-05 starmed

    现场参与，确实很棒

    0